The goal of this clinical trial is to evaluate the Eye Lipid Mobilizer (ELM) for the treatment of evaporative dry eye disease associated with meibomian gland dysfunction. The main questions aim to confirm that 1) the ELM can meet its intended use by validated patient reporting outcomes and 2) to confirm that the ELM device can be used safely by different users within a clinical environment as determined by review of any adverse events related to the use of the device.
The purpose of the clinical study is to evaluate the Eye Lipid Mobilizer for the treatment of evaporative Dry Eye Disease associated with Meibomian Gland Dysfunction. The objective of the study is to confirm that the Eye Lipid Mobilizer (ELM) can meet its intended use by validated patient reporting outcomes. The secondary objective is the ELM device can be used safety with no adverse events. The Eye Lipid Mobilizer (ELM) System is intended for the application of localized heat and vibration therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
31
Treatment of dry eye with ELM device
EYEcenter Optometric
Citrus Heights, California, United States
Procedure-related adverse events
Incidence of procedure-related adverse events will be assessed
Time frame: one week, four weeks
Device-related adverse events
Incidence of device-related adverse events will be assessed
Time frame: one week, four weeks
SPEED II Questionnaire for Dry Eye
Change in outcomes for SPEED II Questionnaire for Dry Eye compared to baseline
Time frame: one week, four weeks
Slip Lamp Evaluation
Change of appearance of cornea under slit lamp evaluation compared to baseline
Time frame: one week, four weeks
Meibomian Gland Imaging
Change in meibomian gland under imaging compared to baseline
Time frame: one week, four weeks
Lipid Layer Thickness
Change in thickness of lipid layer compared to baseline
Time frame: one week, four weeks
Tear Break Up Time
Change in tear break up time compared to baseline
Time frame: one week, four weeks
Corneal Fluorescein Staining
Change in appearance of fluorescein staining compared to baseline
Time frame: one week, four weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.